Best Drug Discovery Software - Page 4

CCG Computer-Aided Molecular Design

CCG is a leading developer and provider of Molecular Modeling, Simulations and Machine Learning software to Pharmaceutical and Biotechnology companies as well as Academic institutions throughout the world. CCG continuously develops new technologies with its team of mathematicians, scientists and software engineers and through scientific collaborations with customers.

Certara Clinical Trial Outcomes Databases

Clinical Trial Outcomes Databases form a quantitative framework to leverage valuable external data, providing key development insights to maximize the probability of success for a new drug. Clinical Trial Outcomes Databases, accessed through our online interactive CODEx interface, provide comprehensive and up-to-date data on major therapeutic areas.

Character Biosciences

Character Biosciences is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.

Chemia

Chemia is a cost effective, compliant and turnkey Electronic Lab Notebook, used in API, Formulation and Analytical Labs, during the Drug Discovery and Development process.

Average Rating: 4.5/5.0

Total Reviews: 1

Chemical

Founded in 2007, Patsnap is the global leader in AI-powered intellectual property (IP) and research and development (R&D) intelligence. We empower professionals in these fields by providing insightful answers that facilitate faster and more confident decision-making. Our domain-specific large language model (LLM), trained on a vast collection of proprietary innovation data, works in conjunction with Hiro, our AI assistant, to deliver actionable insights. These tools enhance productivity by 75% and reduce R&D waste by 25%, streamlining your innovation and commercialization processes. Utilizing advanced Named Entity Recognition (NER), Natural Language Processing (NLP), and Optical Chemical Structure Recognition (OCSR) technologies, Chemical by Patsnap’s comprehensive database consists of over 290 million chemical structures extracted from both patent and non-patent sources, offering unparalleled compound’s structure-patent relationship insights – and is the leading provider for IP and R&D team in the chemical, pharmaceutical, agricultural and other relevant sectors. Key Features: - Chemical by Patsnap is the industry-leading SaaS solution tailored for IP and R&D teams within the life science industry, offering key functionalities such as: - AI-Powered Search: Transform weeks of work into minutes using cutting-edge AI tools designed to navigate the complexities of structure and image retrieval, and automate chemical IP analysis with unmatched precision. - Risk-Proof Innovations: Retrieve all synonyms for chemical structures in a single search and connect them to patents, literature, and clinical data for thorough freedom-to-operate (FTO), novelty, and business analysis. - Fuel Collaboration: Enable your R&D and IP teams to effortlessly share data and expedite compound development through collaborative workspaces and visual reports. - Stay Ahead of Competitors: Visualize and monitor competitor activities globally with an in-depth view of the chemical landscape, allowing you to identify market disruptors, recognize whitespace opportunities, and uncover litigation hotspots.

Chemify

Chemify integrates chemistry with robotics and machine learning to digitize the process of molecule creation.

Chemist-in-the-loop AI

Chemist-in-the-Loop AI by Inductive Bio is an advanced generative design platform that integrates expert medicinal chemistry insights with state-of-the-art machine learning (ML) models to accelerate small molecule drug discovery. Traditional design cycles typically explore around 100 molecular ideas; however, this platform enables chemists to evaluate up to 100,000 ideas per cycle, significantly expanding the chemical space explored. The AI models prioritize designs that offer an optimal balance of potency, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties, and synthetic accessibility. Subsequently, experienced medicinal chemists review these top candidates, develop strategic synthesis plans, and collaborate closely with clients to prioritize, synthesize, test, and iterate on compounds, thereby accelerating the progression to development candidates.

Compound Assist

Compound Assist is much more than a "Cookbook" of formulas. It's a complete business package, from inventory control and ordering support to a print utility that generates machine-scannable bar codes for compounding medications.

Convexia

Convexia is an AI-driven platform designed to revolutionize drug discovery by accelerating the identification and evaluation of overlooked drug assets. By integrating advanced artificial intelligence with expert human review, Convexia streamlines the traditionally lengthy and fragmented drug development process, enabling faster and more efficient progression from asset discovery to clinical trials. Key Features and Functionality: 1. Asset Discovery Agent: Scans global data to identify high-potential drug assets, including preclinical biotech developments and abandoned pharmaceutical intellectual property. 2. Scientific Evaluation Stack: Utilizes over 50 custom-tuned models to conduct in-depth in silico simulations, assessing factors such as binding affinity, toxicity, pharmacokinetics (ADME/PK), immunogenicity, and mechanistic fit. 3. Specialist Human Review: Engages PhD-level experts to validate the scientific viability of each asset, ensuring thorough evaluation of biology, risks, and translatability. 4. Market Insight Agent: Analyzes market factors, including unmet medical needs, competitive landscape, intellectual property positioning, reimbursement signals, and financial projections, to prioritize assets with the highest potential. 5. Operational Risk Agent: Conducts digital twin simulations to assess execution risks before clinical trials commence, evaluating aspects like contract research organization (CRO) stability, manufacturing complexities, site readiness, and potential real-world disruptions. 6. Probability of Success Model: Employs a proprietary model to predict the likelihood of success, aggregating outputs from all agents and benchmarking against historical data to inform go/no-go decisions. 7. Final Human Review: Convenes a roundtable of key opinion leaders (KOLs) in scientific, regulatory, commercial, and clinical domains to align on risk, timing, and exit strategies before finalizing decisions. Primary Value and User Solutions: Convexia addresses the inefficiencies in traditional drug development by significantly reducing the time and resources required to identify and evaluate promising drug assets. By combining AI-driven analysis with expert human oversight, the platform enhances the accuracy and speed of drug discovery, enabling pharmaceutical companies, biotech firms, and investors to uncover and develop therapeutics more effectively. This approach not only accelerates the path to market for new drugs but also increases the likelihood of success by providing comprehensive evaluations and risk assessments at each stage of development.

CovaSyn

CovaSyn is a Model Context Protocol (MCP) platform that gives AI agents real chemistry, pharma, and biotech capability. Instead of switching between ChemDraw, Excel, PubChem, and specialist desktop tools, scientists ask their AI assistant directly, and CovaSyn runs the right tool in the background and returns a result ready to use. The platform provides 199 deterministic tools across 17 suites spanning four workflows: research and discovery (ADMET, druglikeness, protein folding, molecular design); formulation and process development (solubility, crystallization, Arrhenius shelf-life, design of experiments and response-surface optimisation); compliance and safety (ICH M7 mutagenicity, Tox21, ADMET and structural-alert screening); and analytical interpretation (NMR, mass spectrometry, IR, and UV/Vis identification, purity, and impurity profiling). Because the tools are deterministic rather than generative, results are reproducible and auditable: a requirement for regulated pharma and chemistry work. In an independent, peer-reviewed benchmark (MolecularIQ, Klambauer Lab at JKU Linz, ICLR 2026), leading LLMs answered chemistry tasks correctly only 14–41% of the time on their own, and 76–92% when connected to CovaSyn. CovaSyn integrates with Claude, ChatGPT, Cursor, and GitHub Copilot through a single MCP endpoint and API key, is GDPR-ready, and offers a free tier (100 credits per week, no credit card) so teams can evaluate it immediately.

Curi Bio

Curi Bio integrates human stem cells, systems, and AI-enabled data analytics for the development of new therapeutics.

Deargen

DeepCure

DeepCure is a biotechnology company specializing in the development of small molecule therapeutics for immune diseases. Their pipeline includes oral treatments targeting conditions such as rheumatoid arthritis, Still's disease, hidradenitis suppurativa, asthma, and atopic dermatitis. By focusing on innovative drug discovery, DeepCure aims to provide effective solutions for patients suffering from these autoimmune and inflammatory disorders.

Deep MedChem

deepmirror